SCHEMBL6890786

SCHEMBL6890786

Fc1ccc2c(c1)nnn2C1CCNCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
GLA P06280 1/20 0.54
OPRM1 P35372 1/20 0.53
OPRD1 P41143 1/20 0.53
HTT P42858 1/20 0.53
KDM4E B2RXH2 1/20 0.52
USP2 O75604 1/20 0.52
ALOX15 P16050 1/20 0.52
ATM Q13315 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
TSHR P16473 3/20 0.51
CCR3 P51677 1/20 0.50
LMNA P02545 1/20 0.50
PKM P14618 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
GRM5 P41594 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HCAR3 P49019 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10059196 0.82 HCAR3 (0.49) ALDH1A1MEN1KMT2AGLAOPRM1
SCHEMBL4673529 0.82 HCAR3 (0.49) ALDH1A1MEN1KMT2AUSP2NPSR1
SCHEMBL2544136 0.82 LMNA (0.56) ALDH1A1HTTUSP2NPSR1TSHR
Hydrochloric Acid SCHEMBL5857416 0.81 LMNA (0.55) ALDH1A1HTTUSP2NPSR1TSHR
SCHEMBL3137899 0.79 HCAR3 (0.49) ALDH1A1MEN1KMT2AGLANPSR1
SCHEMBL829129 0.78 USP2 (0.52) ALDH1A1MEN1KMT2AGLAHTT
Hydrochloric Acid SCHEMBL29769997 0.78 SMN1; SMN2 (0.48) ALDH1A1NPSR1TSHRLMNAPKM
Hydrochloric Acid SCHEMBL26907902 0.78 SMN1; SMN2 (0.48) ALDH1A1NPSR1TSHRLMNAPKM
Hydrochloric Acid SCHEMBL829074 0.77 USP2 (0.51) ALDH1A1MEN1KMT2AGLAHTT
SCHEMBL4752964 0.75 CCR3 (0.51) ALDH1A1KMT2AKDM4EUSP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6806275-B2 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION NIHON NOHYAKU CO., LTD. (JP) 2004-10-19 US disclosed
CN-1166665-C Arylpiperidine derivatives and use thereof �ձ��ݶ�ũҩ��ʽ���� 2004-09-15 CN disclosed
US-20020156283-A1 Arylpiperidine derivatives and use thereof NIHON NOHYAKU CO., LTD. (JP) 2002-10-24 US disclosed
US-6407121-B1 DOPAMINE D4 RECEPTOR ANTAGONISTS; PSYCHOLOGICAL AND BRAIN DISORDERS; ALZHEIMER*S DISEASE, SCHIZOPHRENIA; SIDE EFFECT REDUCTION NIHON NOHYAKU CO., LTD. (JP) 2002-06-18 US disclosed
EP-1070715-A1 ARYLPIPERIDINE DERIVATIVES AND USE THEREOF Nihon Nohyaku Co., Ltd. (JP) 2001-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156283-A1 Arylpiperidine derivatives and use thereof DRD1, DRD4, DRD2 ALDH1A1 207/4885MEN1 4032/4885KMT2A 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.